Assessment of cardiovascular risk in type 1 diabetes mellitus taking into account various markers of kidney damage


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. assessment of the relationship of markers of diabetic nephropathy (DN) with scales specific for type 1 diabetes mellitus (DM1) and predicting the risk of cardiovascular diseases (CVD). methods. screening of 176 dmi patients was carried out: mean age - 32 years [25.5-42.5]; dmi duration - 15 years [9- 20]; hbaic - 8.2% [7.2-9.6]. Microalbuminuria was not detected in 68.2% of the examined patients, 27% of patients had microalbuminuria, 4.5% had macroalbuminuria; the median albuminuria was 25.5 mg/day [15.o-36.5]. mean egfr (CKD-epi) was 80.55±18.13 ml/min/1.73 m2: ci - 30.i%, C2 - 58.5%, C3a - 8.5% and C3b - 2.9 %. the steno ti risk engine score assessing the 5-year cvd risk was 3.7% [2.i-8.0], the 10-year risk was 7.1% [4.2-8.15]. the Swedish tid risk score, which estimates the 5-year cvd risk, was o.93% [0.50-i.79]. the mean cvd risk in the group was assessed as low according to both scales. results. there was a significant moderate direct correlation of the albuminuria stage and an inverse correlation of egfr with 5-year risk (r=0.388 and r=-0.506; p<0.0001), 10-year risk (r=0.393 and r=-0.500); p<0.0001) according to the steno scale and the Swedish tid risk score (r=0.189; p=0.012 and r=-0.497; p<0.0001). there was a strong positive correlation between the steno risk score and the Swedish risk score (r=0.893; p<0.0001). Conclusion. The steno and Swedish tid risk scales correlate with the DN stage and are equivalent to each other for assessing cardiovascular risk in dmi patients. Swedish tid risk score does not require quantification of albumin loss and is more convenient in clinical practice. Thus, cvd risk assessment in dmi patients can be adequately carried out in routine clinical practice without determining microalbuminuria.

Full Text

Restricted Access

About the authors

A. E Goldschmid

Sechenov First Moscow State Medical University (Sechenov University)

Email: goldsmid93@gmail.com
Endocrinologist Moscow, Russia

R. A Karamullina

Sechenov First Moscow State Medical University (Sechenov University)

Postgraduate student Moscow, Russia

E. I Chechikova

Sechenov First Moscow State Medical University (Sechenov University)

Medical Resident Moscow, Russia

M. V Amosova

Sechenov First Moscow State Medical University (Sechenov University)

Cand. Sci. (Med.), Teaching Assistant at the Department of Endocrinology №1 Moscow, Russia

I. V Poluboyarinova

Sechenov First Moscow State Medical University (Sechenov University)

Cand. Sci. (Med.), Teaching Assistant at the Department of Endocrinology №1 Moscow, Russia

V. V Fadeev

Sechenov First Moscow State Medical University (Sechenov University)

Corresponding member of RAS, Dr. Sci. (Med.), Professor, Director of the Clinic, Head of the Department of Endocrinology № 1 Moscow, Russia

References

  1. Sharma H., Lencioni M., Narendran P. Cardiovascular disease in type 1 diabetes. Cardiovasc. Endocrinol. Metab. 2019;8(1):28-34. Doi:10.1097/ XCE.0000000000000167.
  2. Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiology of diabetes mellitus in Russian Federation: Clinical and statistical report according to the federal diabetes registry. Diab. Mellit. 2017;20(1):13-41. doi: 10.14341/DM8664.
  3. Morimoto A., Onda Y., Nishimura R., et al. Cause-specific mortality trends in a nationwide population-based cohort of childhood-onset type 1 diabetes in Japan during 35 years of follow-up: the DERI Mortality Study. Diabetol. 2013;56(10):2171-5. doi: 10.1007/s00125-013-3001-2.
  4. Libby P., Nathan D.M., Abraham K., et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation. 2005;111(25):3489-93. Doi: 10.1161/ CIRCULATIONAHA.104.529651.
  5. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetol. 1991;34(12):877-90.
  6. Soedamah-Muthu S.S., Fuller J.H., Mulnier H.E., Raleigh V.S., Lawrenson R.A., Colhoun H.M. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diab. Care. 2006;29(4):798-804. Doi: 10.2337/ diacare.29.04.06.dc05-1433.
  7. Mattock M.B., Morrish N.J., Viberti G., Keen H., Fitzgerald A.P., Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41(6):736-41. Doi: 10.2337/ diab.41.6.736.
  8. Wu T., McGrath K.C.Y, Death A.K. Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers? Vasc. Health. Risk Manag. 2005;1(4):309-16. doi: 10.2147/vhrm.2005.1.4.309.
  9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. (London, England). 1998;352(9131):837-53.
  10. de Zeeuw D., Remuzzi G., Parving H-H., et al. Albuminuria, a therapeutic targetfor cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921-7. doi: 10.1161/01.CIR.0000139860.33974.28.
  11. Anavekar N.S., Gans D.J., Berl T., et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int. 2004;92( Suppl.):S50-5. Doi: 10.1111/j. 1523-1755.2004.09213.x.
  12. Cederholm J., Eeg-Olofsson K., Eliasson B., Zethelius B., Gudbjornsdottir S. A new modelfor 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diab. Med. 2011;28(10):1213- 20. doi: 10.1111/j.1464-5491.2011.03342.x.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies